Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE

User menu

  • Log out
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log out
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE
PreviousNext
Articles, Cellular/Molecular

Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine's Effects

Estefanía Moreno, David Moreno-Delgado, Gemma Navarro, Hanne M. Hoffmann, Silvia Fuentes, Santi Rosell-Vilar, Paola Gasperini, Mar Rodríguez-Ruiz, Mireia Medrano, Josefa Mallol, Antoni Cortés, Vicent Casadó, Carme Lluís, Sergi Ferré, Jordi Ortiz, Enric Canela and Peter J. McCormick
Journal of Neuroscience 5 March 2014, 34 (10) 3545-3558; https://doi.org/10.1523/JNEUROSCI.4147-13.2014
Estefanía Moreno
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Moreno-Delgado
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gemma Navarro
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanne M. Hoffmann
4Neuroscience Institute and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitat Autónoma de Barcelona, 08193 Bellaterra, Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Fuentes
4Neuroscience Institute and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitat Autónoma de Barcelona, 08193 Bellaterra, Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santi Rosell-Vilar
4Neuroscience Institute and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitat Autónoma de Barcelona, 08193 Bellaterra, Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Gasperini
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mar Rodríguez-Ruiz
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireia Medrano
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefa Mallol
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoni Cortés
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicent Casadó
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carme Lluís
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergi Ferré
5National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Ortiz
4Neuroscience Institute and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitat Autónoma de Barcelona, 08193 Bellaterra, Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enric Canela
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. McCormick
1Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
2Institute of Biomedicine of the University of Barcelona (IBUB) and
3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, 08028 Spain,
6School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, United Kingdom NR4 7TJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Cocaine alters the functional characteristics of D1R-H3R heteromers in transfected cells. a–c, f, Neuroblastoma SK-N-MC cells stable expressing D1R and H3R were not treated or treated overnight with 30 μm cocaine. a, b, cAMP production was determined after 10 min stimulation with D1R agonist SKF 38393 (1 μm) or the H3R agonist imetit (1 μm) (a) or with D1R agonist SKF 81297 (100 nm) or the H3R agonist RAMH (100 nm) (b) in the absence or in the presence of 0.5 μm forskolin. Values (cAMP produced in each condition minus basal stimulation in the absence of forskolin or agonists) represent mean ± SEM, n = 4–8. One-way ANOVA followed by Bonferroni post hoc test showed a significant (*p < 0.05, **p < 0.01, ***p < 0.001) effect over basal (cells not stimulated) or (#p < 0.05, ###p < 0.001) over forskolin effect (cells stimulated with forskolin). c, f, Cells infected with the empty virus vector (c) or infected with lentiviral particles expressing shRNA (shσ1R) to silence the receptor (f) were treated for 30 min with the D1R antagonist SCH 23390 (1 μm) or the H3R antagonist thioperamide (1 μm) before the addition of SKF 38393 (100 nm) or imetit (100 nm) for an additional incubation period of 10 min and ERK 1/2 phosphorylation was determined by Western blot. Values represent mean ± SEM (n = 3–5) of percentage of phosphorylation relative to basal levels found in untreated cells. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (*p < 0.05, **p < 0.01) effect over basal or of the antagonist plus agonist treatment over the agonist treatment (#p < 0.05). d, β-Arrestin 1 recruitment was measured by BRET experiments in HEK293T cells 48 h post-transfection with 2 μg of cDNA corresponding to D1R, 1 μg of cDNA corresponding to β-arrestin 1-Rluc, and 3 μg of cDNA corresponding to H3R-YFP. Cells were not treated (BRET < 10) or treated for 30 min with 30 μm cocaine, 1 μm SCH 23390, or 1 μm thioperamide alone or in combination before 10 min stimulation with SKF 38393 (100 nm) or imetit (100 nm). Values represent mean ± SEM, n = 4. One-way ANOVA followed by Bonferroni post hoc tests showed a significant effect over basal (**p < 0.01, ***p < 0.001) or of the antagonist plus agonist treatment over the agonist treatment (##p < 0.01, ###p < 0.001). e, σ1R expression was determined after silencing of σ1R by shRNA. Neuroblastoma SK-N-MC cells stable expressing D1R and H3R were infected with lentiviral particles containing either control (LV control) or shRNA specific for σ1R (LV sh σ1R) and the relative expression levels were tested using quantitative RT-PCR. Results are expressed as an average of three replicates.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    σ1R-D1R-H3R complexes detected by energy transfer experiments. a, c, d, BRET saturation experiments were performed using HEK293T cells 48 h post-transfection with 0.2 μg of cDNA corresponding to H3R-Rluc (a) or 0.15 μg of cDNA corresponding to D1R-Rluc (c, d) and increasing amounts of cDNA corresponding to σ1R-YFP (a; 0.1–0.5 μg cDNA) or H3R-YFP (c, d; 0.2–1.5 μg cDNA). Cells were treated for 30 min (a, c) or 24 h (d) with medium (red lines) or with 30 μm cocaine (black lines) prior BRET determination. c, d, Cells were also transfected with siRNA for σ1R (see Materials and Methods; green line). Both fluorescence and luminescence of each sample were measured before every experiment to confirm similar donor expressions (∼110,000 bioluminescence units) while monitoring the increase in acceptor expression (10,000–40,000 fluorescence units). b, SRET saturation experiments were performed using HEK293T cells 48 h post-transfection with 0.3 μg of cDNA corresponding to H3R-Rluc, 0.23 μg of cDNA corresponding to σ1R-GFP2, and increasing amounts of cDNA corresponding to D1R-YFP (0.05–0.6 μg). Cells were treated for 30 min with medium (red lines) or with 30 μm cocaine (black lines) prior to SRET determination. The relative amount of BRET or SRET is given as a function of 100 × the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET and SRET are expressed as mBU or mSU, respectively, and values are means ± SEM; three to four different experiments grouped as a function of the amount of acceptor. a, b, Top, A schematic representation of the BRET (a) and SRET (b) techniques is shown.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Expression of σ1R-D1R-H3R complexes in the mouse striatum detected by coimmunoprecipitation and PLA experiments. a–d, Coimmunoprecipitation experiments are shown. Striatal slices from WT and σ1R KO mice were untreated or treated with 150 μm cocaine for 30 min (cocaine). Solubilized striatal membranes (a) and immunoprecipitates with anti-D1R antibody or anti-calnexin antibody as negative control (NC; b–d) were analyzed by SDS-PAGE and immunoblotted using anti-D1R antibody (b), anti-H3R antibody (c), or anti-σ1R antibody (c). IP, immunoprecipitation; WB, Western blotting; MW, molecular mass. e–m, PLAs were performed as indicated in Materials and Methods, using WT (e–g) or σ1R KO mice (h–j) striatal slices. D1R-H3R (e, h), σ1R-D1R (f, i), and σ1R-H3R (g, j) heteromers were visualized as red spots around blue-colored DAPI-stained nucleus. k–m, Negative controls were performed doing the PLA experiments in WT mouse striatal slices incubated with only anti D1R (k), anti-σ1R (l), or anti-H3R (m) antibody as primary antibodies. Cell nuclei were stained with DAPI (blue). For each part a magnification is shown. Scale bar, 20 μm.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Expression of σ1R-D1R-H3R complexes in the rat striatum detected by coimmunoprecipitation and PLA experiments. a–d, Coimmunoprecipitation experiments are shown. Rat striatal slices were untreated or treated with 150 μm cocaine for 30 min (cocaine). Solubilized striatal membranes (a) and immunoprecipitates with anti-D1R antibody or anti-calnexin antibody as negative control (NC; b–d) were analyzed by SDS-PAGE and immunoblotted using anti-D1R antibody (b), anti-H3R antibody (c), or anti-σ1R antibody (c). IP, immunoprecipitation; WB, Western blotting; MW, molecular mass. e–g, PLAs were performed as indicated in Materials and Methods, using rat striatal slices. D1R-H3R (e), σ1R-D1R (f), and σ1R-H3R (g) heteromers were visualized as red spots around blue–colored DAPI-stained nucleus. Scale bar, 20 μm.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Cocaine inhibits the H3R signaling and the D1R-H3R cross-antagonism in ERK 1/2 phosphorylation in mouse striatum. WT (a) and σ1R KO (b) mouse striatal slices were treated or not with 150 μm cocaine for 2 h and were preincubated for 20 min with medium, the D1R antagonist SCH 23390 (10 μm), or the H3R antagonist thioperamide (10 μm) before the addition of the D1R agonist SKF 38393 (1 μm) or the H3R agonist imetit (1 μm) for an additional incubation period of 10 min. ERK 1/2 phosphorylation was determined by Western blot. Immunoreactive bands from three to eight slices obtained from eight WT or KO animals were quantified for each condition. Values represent mean ± SEM percentage of phosphorylation relative to basal levels found in untreated slices. No significant differences were obtained between the basal levels of the WT and the σ1R KO mice. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (*p < 0.05) effect over basal or of the antagonist plus agonist treatment over the agonist treatment (#p < 0.05, ##p < 0.01).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Cocaine inhibits the H3R-mediated modulation of D1R-promoted ERK 1/2 phosphorylation in rat striatum. Striatal slices from naive rats treated or not with 150 μm cocaine for 2 h (a, b) and striatal slices from sham rats or rats acutely treated (24 h) with cocaine (c, d), or striatal slices from sham rats or 9 weeks cocaine self-administered rats (e, f) were preincubated for 20 min with medium, the D1R antagonist SCH 23390 (10 μm), or the H3R antagonist thioperamide (10 μm) before the addition of the D1R agonist SKF 38393 (1 μm) or the H3R agonist imetit (1 μm) for an additional incubation period of 10 min and ERK 1/2 phosphorylation was determined by Western blot. Immunoreactive bands from 3 to 10 slices obtained from four animals were quantified for each condition. Values represent mean ± SEM percentage of phosphorylation relative to basal levels found in untreated slices. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (*p < 0.05, **p < 0.01, ***p < 0.001) effect over basal or of the antagonist plus agonist treatment over the agonist treatment (#p < 0.05, ##p < 0.01, ###p < 0.001).

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Receptor expression in the striatum of cocaine acutely treated rats compared with sham rats. The expression of H3R (white bars), D1R (gray bars), and σ1R (black bars) in striatal membranes from a pool (n = 5) of sham rats or rats acutely treated (24 h) with cocaine (cocaine) was determined by competition experiments of [3H]RAMH (3 nm) versus RAMH, [3H]SCH 23390 (2 nm) versus SCH 23390, or [3H] YM-09151-02 (2 nm) versus PRE-084, respectively. Competition curves were monophasic and binding data were fitted to Equations 4 or 5 (see Materials and Methods) to calculate the maximum binding.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Cocaine inhibits the H3R-mediated modulation of D1R-promoted cell death in organotypic striatal slice cultures. Organotypic cultures of rat striatal slices were prepared as indicated (see Materials and Methods) and after 24 h, culture medium was replaced by fresh medium containing no ligands (a) or 150 μm cocaine (c). After 1 h, vehicle or 10 μm SCH 23390, imetit, or thioperamide were added and incubated for an additional 1 h before the addition of the D1R agonist SKF 38393 (50 μm) and slices were maintained 48 h more in culture. As a control, cell death induced by 1 mm glutamate in the presence or in the absence of 10 μm imetit was analyzed (b). Cell death was determined by DAPI and PI staining as indicated (see Materials and Methods). Values represent mean ± SEM percentage of PI stained cells versus total DAPI-stained cells determined in six to eight fields from two to three independent organotypic cultures. Bifactorial ANOVA showed a significant (***p < 0.001) effect over basal corresponding to nontreated organotypic cultures. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (***p < 0.001) effect over basal corresponding to nontreated organotypic cultures or of organotypic cultures treated with two ligands respect to the cultures treated with SKF 38393 (###p < 0.001).

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9.

    Effect of σ1R agonist and antagonists on the H3R-mediated modulation of the D1R-promoted cell death and signaling in the striatum. Rat striatal organotypic cultures (a–c) or striatal slices (d–f) were prepared as indicated (see Materials and Methods) and were treated for 1 h with medium (a, d) or PD 144418 (10 μm; b, c, e, f) before adding 1 μm PRE-084 (a, d), vehicle (b, e), or 150 μm cocaine (c, f). At 24 h of organotypic culture (a–c) or after 2 h of slice incubation (d–f) the D1R antagonist SCH 23390 (50 μm, a–c or 10 μm, d–f) or the H3R antagonist thioperamide (10 μm) were added 20 min before the addition of the D1R agonist SKF 38393 (50 μm, a–c or 1 μm, d–f) or the H3R agonist imetit (10 μm, a–c or 1 μm, d–f) alone or in combination. Striatal organotypic cultures were cultured for an additional 48 h and slices were incubated for an additional 10 min and were processed to determine cell death or ERK 1/2 phosphorylation, respectively, as indicated in Materials and Methods. a–c, Values represent mean ± SEM percentage of PI stained cells versus total DAPI-stained cells determined in four to six fields from two to three independent organotypic cultures. d–f, Values represent mean ± SEM phosphorylation relative to basal levels found in untreated slices, determined in 3–10 slices obtained from four animals. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (*p < 0.05, ***p < 0.001) effect over basal (nontreated organotypic cultures or slices) or of the two ligands treatment over the agonist treatment (#p < 0.05, ###p < 0.001).

  • Figure 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 10.

    Scheme representing the D1R signaling in the D1R-H3R heteromer in the absence or presence of cocaine. In GABAergic neurons (gray), in the absence of cocaine, H3R (blue) and D1R (red) form heteromers to which σ1R (yellow) can bind. Activation of only the D1R protomer (a) promotes a decrease of cAMP levels in accordance with Gi (orange) coupling of both receptors in the heteromer. Moreover, D1R activation induces β-arrestin (purple) recruitment and promotes ERK 1/2 phosphorylation. Upon dual stimulation of the heteromer with both H3R and D1R agonists in the absence of cocaine (b), a negative cross-talk (the ability of one receptor agonist to negatively modulate the partner receptor ligand binding or signaling) between receptors in the heteromer occurs, inhibiting β-arrestin recruitment and subsequently reducing ERK 1/2 phosphorylation from the heteromer. When cocaine (brown) binds to σ1R (c) this induces structural changes in the heteromer disrupting the negative cross-talk. Thus, the H3R-mediated brake on D1R is lost, allowing D1R (green) to couple to Gs (pale green) and increasing cAMP. Importantly, β-arrestin recruitment and ERK 1/2 phosphorylation are also detected in the presence of cocaine.

Tables

  • Figures
    • View popup
    Table 1.

    Cocaine blocks the positive allosteric interaction between D1R and H3R.

    Competition experiment ([3H]SCH vs SKF38393)Parameters
    KD1 (nm)KD2 (nm)
    Not treated rats in the absence of cocaine
        Control31 ± 41100 ± 200
        +RAMH14 ± 1*320 ± 10*
    Not treated rats in the presence of cocaine
        Control28 ± 21000 ± 100
        +RAMH30 ± 41100 ± 200
    Cocaine acutely treated rats
        Control28 ± 4440 ± 60
        +RAMH19 ± 4390 ± 40
    Sham rats
        Control26 ± 4700 ± 100
        +RAMH3 ± 2**130 ± 40**
    Cocaine self-administered rats
        Control33 ± 6800 ± 200
        +RAMH37 ± 91900 ± 600
    • ↵Competition curves of the D1R antagonist [3H]SCH 23390 (2 nm) binding versus increasing concentrations of the D1R agonist SKF 38393 were performed in the absence or the presence of 2 nm of the H3R agonist RAMH using striatal membranes from control rats treated or not with 30 μm cocaine for 30 min, rats acutely treated with cocaine, or cocaine self-administered rats. KD1 and KD2 are, respectively, the equilibrium dissociation constants of SKF 38393 binding to D1R and were determined by fitting binding data to Equation 3. Parameters are mean ± SEM (n = 3). For each group, significant differences with respect to control were calculated by an unpaired Student's t test (*p < 0.05, **p < 0.01).

Back to top

In this issue

The Journal of Neuroscience: 34 (10)
Journal of Neuroscience
Vol. 34, Issue 10
5 Mar 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine's Effects
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine's Effects
Estefanía Moreno, David Moreno-Delgado, Gemma Navarro, Hanne M. Hoffmann, Silvia Fuentes, Santi Rosell-Vilar, Paola Gasperini, Mar Rodríguez-Ruiz, Mireia Medrano, Josefa Mallol, Antoni Cortés, Vicent Casadó, Carme Lluís, Sergi Ferré, Jordi Ortiz, Enric Canela, Peter J. McCormick
Journal of Neuroscience 5 March 2014, 34 (10) 3545-3558; DOI: 10.1523/JNEUROSCI.4147-13.2014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine's Effects
Estefanía Moreno, David Moreno-Delgado, Gemma Navarro, Hanne M. Hoffmann, Silvia Fuentes, Santi Rosell-Vilar, Paola Gasperini, Mar Rodríguez-Ruiz, Mireia Medrano, Josefa Mallol, Antoni Cortés, Vicent Casadó, Carme Lluís, Sergi Ferré, Jordi Ortiz, Enric Canela, Peter J. McCormick
Journal of Neuroscience 5 March 2014, 34 (10) 3545-3558; DOI: 10.1523/JNEUROSCI.4147-13.2014
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Memory Retrieval Has a Dynamic Influence on the Maintenance Mechanisms That Are Sensitive to ζ-Inhibitory Peptide (ZIP)
  • Neurophysiological Evidence for a Cortical Contribution to the Wakefulness-Related Drive to Breathe Explaining Hypocapnia-Resistant Ventilation in Humans
  • Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase
Show more Articles

Cellular/Molecular

  • Widely Used CaMKII Regulatory Segment Mutations Cause Tight Actinin Binding and Dendritic Spine Enlargement in Unstimulated Neurons
  • High-Pressure Freezing EM Tomography of Entire Ribbon Synapses in the Retina
  • Identifying Key Regulators in Odorant Receptor Trafficking
Show more Cellular/Molecular
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Accessibility
(JNeurosci logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.